Details of the Drug

General Information of Drug (ID: DMA6LR3)

Drug Name
OV101
Synonyms Gaboxadol
Indication
Disease Entry ICD 11 Status REF
Angelman syndrome LD90.0 Phase 3 [1]
Fragile X syndrome LD55 Phase 2 [2]
Cross-matching ID
TTD ID
DKI03V
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor (GABAR) TTCI43M NOUNIPROTAC Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03882918) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03697161) A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome. U.S.National Institutes of Health.
3 Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.